Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08656795 in Adults With Overweight or Obesity
NCT07876518Phase 1Not yet recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Primary completion
- Nov 2028
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing PF-08656795 with Placebo (2 arms). Primary endpoint: Incidence of Treatment Emergent Adverse Events at 12 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
PF-08656795
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07876518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876518.